Wegovy for MASH: ESSENCE Trial Results + FDA Approval Pathway

In August 2025 the FDA approved Wegovy (semaglutide 2.4 mg weekly) for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate- to-advanced liver fibrosis. The approval rested on ESSENCE (Sanyal 2025, NEJM^[1]), a 1,197-patient phase 3 trial that hit both co-primary histologic endpoints: 62.9% of the semaglutide arm achieved MASH resolution without worsening of fibrosis at week 72 vs 34.3% on placebo, and 36.8% achieved fibrosis improvement by at least one stage without worsening of MASH vs 22.4% on placebo. Wegovy joins resmetirom (Rezdiffra, Harrison 2024^[2]) as the second drug in any class with an FDA-approved MASH indication — and is the first GLP-1 to carry one. This article walks through the ESSENCE design, the F2/F3 fibrosis criteria the label requires, the hepatology workup the indication assumes, and how Wegovy and Rezdiffra fit together in the new MASH pathway.

The honest summary

• ESSENCE is real and well-designed. 1,197 adults with biopsy-confirmed MASH and F2 or F3 fibrosis randomized 2:1 to semaglutide 2.4 mg weekly or placebo, paired liver biopsies at week 72, two pre-specified histologic co-primary endpoints. Both endpoints hit with highly significant separation (Sanyal 2025^[1]).
• The label is narrow on purpose. Wegovy MASH covers F2–F3 (significant or advanced fibrosis) but not F4 cirrhosis. F4 patients have a separate management pathway and were not included in ESSENCE.
• The diagnosis can be noninvasive. Most hepatologists now stage fibrosis with vibration-controlled transient elastography (FibroScan / VCTE) and FIB-4, not biopsy. AASLD 2023 practice guidance (Rinella 2023^[8]) anchors this workflow.
• Rezdiffra is a different mechanism. Resmetirom (Harrison 2024^[2]) is a liver- selective thyroid hormone receptor-beta agonist. It hit MASH resolution at 26–30% and fibrosis improvement at 24–26% on 80–100 mg in MAESTRO-NASH. Wegovy delivers larger effect sizes but adds GLP-1 GI side effects and is injectable.
• Tirzepatide is coming. SYNERGY-NASH (Loomba 2024^[3]) phase 2 showed 51–62% MASH resolution across the three tirzepatide doses vs 10% on placebo, but a phase 3 readout is still pending; Zepbound does not carry an FDA MASH indication as of May 2026.

What ESSENCE actually showed

ESSENCE (Sanyal 2025, NEJM^[1]) enrolled 1,197 adults with biopsy-confirmed MASH and fibrosis stage F2 (significant) or F3 (advanced) by the central pathology panel. Patients were randomized 2:1 to semaglutide 2.4 mg weekly or matching placebo, with paired liver biopsies at baseline and week 72. The two co-primary endpoints both required no worsening of the other histologic axis — you could not trade MASH resolution for fibrosis progression or vice versa.

• MASH resolution without worsening of fibrosis: 62.9% on semaglutide vs 34.3% on placebo (estimated difference +28.6 percentage points).
• Fibrosis improvement by ≥ 1 stage without worsening of MASH: 36.8% on semaglutide vs 22.4% on placebo (estimated difference +14.4 percentage points).
• Body-weight loss: the semaglutide arm lost roughly 10–11% of body weight at week 72, in line with the STEP-1 obesity trial readout (Wilding 2021^[6]).
• Safety: the GI profile (nausea, constipation, diarrhea) matched prior semaglutide trials; serious hepatobiliary events were uncommon.

The phase 2 precursor (Newsome 2021^[7]) had already signaled the effect — 59% NASH resolution on 0.4 mg daily semaglutide vs 17% on placebo. ESSENCE confirmed it at scale with the standard weekly 2.4 mg dose used in obesity.

The MASH/MASLD terminology, briefly

The 2023 multi-society Delphi statement (Rinella 2023^[4]) replaced “NAFLD” with “MASLD” (metabolic dysfunction-associated steatotic liver disease) and “NASH” with “MASH” (metabolic dysfunction-associated steatohepatitis). The new terms require at least one cardiometabolic risk factor (BMI ≥ 25, T2D, dyslipidemia, hypertension) alongside the imaging or histologic finding of steatosis. The spectrum is MASLD → MASH → F1–F4 fibrosis → cirrhosis → hepatocellular carcinoma. ESSENCE used the MASH term; the FDA labeling uses MASH.

The F2/F3 criterion and how it gets confirmed

The Wegovy MASH label restricts treatment to non-cirrhotic patients with F2 or F3 fibrosis — the same population ESSENCE enrolled. AASLD 2023 practice guidance (Rinella 2023^[8]) walks through the noninvasive workup:

1. FIB-4 first. Calculated from age, AST, ALT, and platelet count (Sterling 2006^[10], validated for NAFLD by Vilar-Gomez 2018^[11]). FIB-4 < 1.3 has a high negative predictive value to rule out advanced fibrosis; FIB-4 > 2.67 is a positive trigger for hepatology referral.
2. FibroScan / VCTE next. Vibration-controlled transient elastography (Eddowes 2019^[9]) reports liver stiffness in kPa. Typical cutoffs: < 8 kPa unlikely F2+, 8–12 kPa indeterminate, > 12 kPa likely F3+, > 20 kPa concerning for F4. The CAP score on the same machine quantifies steatosis.
3. ELF blood test as an alternative. The enhanced liver fibrosis panel (hyaluronic acid, TIMP-1, and PIIINP) is a noninvasive serum option used when FibroScan is unavailable.
4. Biopsy when necessary. Biopsy remains the historical gold standard and is still used when noninvasive testing is discordant or when ruling out competing diagnoses (autoimmune hepatitis, drug-induced liver injury). Prior authorization workflows vary on whether biopsy is required.

The practical pathway most clinics are settling on: primary care or obesity medicine orders FIB-4 plus a FibroScan; if the patient screens into F2–F3, refer to hepatology; hepatology confirms, documents the indication, and supports the prior authorization for Wegovy under the MASH label.

Wegovy MASH vs Rezdiffra: head-to-head, on paper

Rezdiffra (resmetirom) was FDA approved in March 2024 for non-cirrhotic MASH with F2 or F3 fibrosis based on MAESTRO-NASH (Harrison 2024, NEJM^[2]). It is a once-daily oral, liver-selective thyroid hormone receptor- beta agonist. The endpoint structure was nearly identical to ESSENCE, which makes the cross-trial comparison cleaner than usual:

• Rezdiffra 80 mg / 100 mg vs placebo: MASH resolution 25.9% / 29.9% vs 9.7%; fibrosis improvement 24.2% / 25.9% vs 14.2% (Harrison 2024^[2]).
• Wegovy 2.4 mg vs placebo: MASH resolution 62.9% vs 34.3%; fibrosis improvement 36.8% vs 22.4% (Sanyal 2025^[1]).

The headline gap is real, but the comparison comes with caveats. The placebo response in ESSENCE was much higher than in MAESTRO-NASH, which probably reflects differences in the lifestyle counseling protocol and patient population. Wegovy also produced 10–11% body-weight loss while Rezdiffra is weight-neutral; in patients who also need obesity treatment or who carry SELECT-style cardiovascular risk (Lincoff 2023^[5]), Wegovy is doing more work per dose. The Rezdiffra advantages are the oral route, no GLP-1 GI side effects, and a label that includes patients already at goal weight.

Magnitude: MASH resolution at week 72

Where tirzepatide sits

SYNERGY-NASH (Loomba 2024, NEJM^[3]) was a phase 2 trial of tirzepatide 5, 10, or 15 mg weekly vs placebo in 190 adults with biopsy-confirmed MASH and F2 or F3 fibrosis. MASH resolution without fibrosis worsening: 43.6%, 55.5%, and 62.4% across the three tirzepatide arms vs 10.0% on placebo. The effect size on the 15 mg arm is comparable to ESSENCE, but SYNERGY-NASH is a smaller phase 2 study. A tirzepatide phase 3 MASH program is under way; until it reads out, Zepbound does not carry an FDA MASH indication. Clinicians treating a patient with both obesity and MASH today can legitimately prescribe Wegovy under the MASH label or Zepbound under the obesity label, depending on insurance and tolerability.

The practical pathway for a patient with F2/F3 MASH

1. Confirm fibrosis stage. FIB-4 + FibroScan (or ELF) at baseline. If F2/F3 confirmed and F4 ruled out, continue to step 2. If FibroScan > 20 kPa or clinical features suggest cirrhosis, the patient is outside the Wegovy MASH label and needs a hepatology-led cirrhosis workup instead.
2. Document the indication. Most payers require chart documentation of MASH with F2/F3 fibrosis, a relevant ICD-10 code (K75.81 for NASH or the newer MASH code where adopted), and often six months of supervised intensive lifestyle intervention.
3. Submit the prior authorization. Wegovy MASH PAs typically ask for the FibroScan or biopsy result, the FIB-4, recent LFTs, and lifestyle-intervention history. Some Medicaid programs (Vermont was an early adopter) carve MASH out of the obesity exclusion that otherwise blocks Wegovy.
4. Initiate Wegovy. Standard dose ladder: 0.25 mg weekly for 4 weeks, then 0.5, 1.0, 1.7, 2.4 mg with a 4-week interval at each step. Maintenance is 2.4 mg weekly.
5. Monitor. AST, ALT, FIB-4 at 3 months and every 6 months thereafter. Repeat FibroScan at 12 months (and again at 24 months if treatment continues). Track weight, blood pressure, A1c.
6. Re-evaluate at 12 months. If FibroScan stiffness has dropped and FIB-4 trend is favorable, the patient is responding biochemically and on the histologic trajectory ESSENCE documented. If LFTs are rising or FibroScan is worsening, re-stage and consider re-biopsy or Rezdiffra add-on (off-label combination, not yet studied in trials).

Insurance and cost reality

Wegovy retail is around $1,349 per month before benefits. Commercial plans that exclude obesity often cover Wegovy under the MASH indication once the F2/F3 documentation is in place; the MASH approval functionally created a second coverage path in plans that previously denied for obesity. Medicare Part D plans add Wegovy under the MASH and CV-risk labels (the SELECT indication, Lincoff 2023^[5]), not under the obesity label. State Medicaid coverage is moving faster on MASH than on obesity; documentation of F2/F3 fibrosis is decisive in most state PA reviews. Compounded semaglutide is not a substitute — the ESSENCE data, the FDA approval, and the label are all specific to FDA-approved Wegovy 2.4 mg, and the FDA shortage list for semaglutide has been resolved.

Related research and tools

• Wegovy for MASH, MAFLD & fatty liver evidence review — the longer-form ESSENCE walkthrough with the MASLD/MASH terminology and the AASLD lifestyle adjuncts
• GLP-1 fatty liver and MASH patient guide — the patient-facing primer on MASLD/MASH and how GLP-1s fit
• Does a GLP-1 cause liver damage? — the safety picture, transient LFT elevations, and the rare hepatobiliary signals
• Mounjaro vs Zepbound switching — tirzepatide labels and how a patient with both T2D and MASH gets to the right brand
• FLOW trial semaglutide and kidney disease — the parallel CKD indication story; same drug, same dose, different organ

Important disclaimer. This article is educational and does not constitute medical advice. MASH diagnosis and Wegovy treatment under the MASH indication require clinician evaluation. Patients with cirrhosis (F4) are not candidates for Wegovy under the MASH label and need a hepatology-led management pathway including HCC surveillance. FibroScan / VCTE cutoffs vary by device and cohort; the values in this article are typical ranges and not universal thresholds. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 6 months, or sooner if the SYNERGY-NASH phase 3 readout, a Zepbound MASH approval, or new AASLD practice guidance materially changes the pathway.